Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Superficial Bladder Urothelial Carcinoma”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Testing effectiveness (Phase 2)Study completedNCT00393809
What this trial is testing

Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer

Who this might be right for
Bladder Neoplasms
Hebrew University of Jerusalem 18
Not applicableUnknownNCT05276167
What this trial is testing

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Who this might be right for
High-Risk, Non-Muscle Invasive Bladder Urothelial CarcinomaPerfusion; ComplicationsIntraoperative Complications
Henan Cancer Hospital 40
Testing effectiveness (Phase 2)Study completedNCT00002917
What this trial is testing

Paclitaxel in Treating Patients With Early-Stage Bladder Cancer

Who this might be right for
Bladder Cancer
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Large-scale testing (Phase 3)Study completedNCT00003814
What this trial is testing

Eflornithine in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 450
Testing effectiveness (Phase 2)UnknownNCT04730232
What this trial is testing

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
High-RiskNon-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 63
Early research (Phase 1)Looking for participantsNCT06766266
What this trial is testing

Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

Who this might be right for
Non-Muscle Invasive Bladder Urothelial Carcinoma
First Affiliated Hospital of Chongqing Medical University 18
Not applicableLooking for participantsNCT07302230
What this trial is testing

Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial

Who this might be right for
Localized Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of Washington 100
Testing effectiveness (Phase 2)Study completedNCT01687244
What this trial is testing

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Who this might be right for
Superficial Bladder Cancer
FKD Therapies Oy 40
Large-scale testing (Phase 3)Study completedNCT00004154
What this trial is testing

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Who this might be right for
Bladder Cancer
M.D. Anderson Cancer Center 111
Very early researchStudy completedNCT00734994
What this trial is testing

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

Who this might be right for
Transitional Cell Carcinoma of BladderSuperficial Bladder Cancer
Mark Dewhirst 15
Post-approval studies (Phase 4)Looking for participantsNCT05962541
What this trial is testing

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Who this might be right for
Non-muscle-invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial CarcinomaHigh Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza 327
Large-scale testing (Phase 3)Not Yet RecruitingNCT07464145
What this trial is testing

NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc. 393
Large-scale testing (Phase 3)UnknownNCT00003725
What this trial is testing

Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Who this might be right for
Bladder Cancer
Anthra Pharmaceuticals 300
Not applicableStudy completedNCT06020807
What this trial is testing

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

Who this might be right for
Non Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
Nucleix Ltd. 168
Large-scale testing (Phase 3)Ended earlyNCT00191477
What this trial is testing

Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

Who this might be right for
Bladder Neoplasms
Eli Lilly and Company 355
Testing effectiveness (Phase 2)Study completedNCT00047216
What this trial is testing

Tipifarnib in Treating Patients With Recurrent Bladder Cancer

Who this might be right for
Bladder Cancer
University Health Network, Toronto
Large-scale testing (Phase 3)WithdrawnNCT07313891
What this trial is testing

Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) CancerUrothelial Carcinoma Bladder+1 more
Relmada Therapeutics, Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
National Cancer Institute (NCI) 161
Testing effectiveness (Phase 2)Study completedNCT04496219
What this trial is testing

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Urothelial Carcinoma In SituRecurrent Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+3 more
Fred Hutchinson Cancer Center 45
Large-scale testing (Phase 3)Study completedNCT00406068
What this trial is testing

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Neoplasms
Bioniche Life Sciences Inc. 129
Load More Results